ArticleAfrican journal of thoracic and critical care medicine2025
The clinical and chest radiographic features of respiratory syncytial virus-associated severe respiratory illness in hospitalised adults in South Africa, 2022 - 2023.
Article in African journal of thoracic and critical care medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Risk factors for ICU admission in hospitalized children with respiratory syncytial virus infection.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In most healthy adults, respiratory syncytial virus (RSV) causes mild self-limiting respiratory infection. However, vulnerable populations may present differently or have more complicated courses of disease. Objectives: To describe the clinical and radiographic features of adults hospitalised with RSV-associated severe respiratory illness (SRI) in two urban hospitals during 2022 and 2023. Methods: Patients aged ≥18 years were enrolled through systematic sentinel surveillance for SRI. Clinical characteristics and radiographic profiles of RSV-infected adults were reviewed. Results: Eighteen (2%) of 916 enrolled hospitalised patients with SRI tested positive for RSV at the two hospitals. Other pathogens detected included SARS-CoV-2 (n=69/916; 8%), influenza (n=49/916; 5%) and pertussis (n=10/916; 1%). The median (range) age was 50 (35 - 75) years, and 12 (67%) were female. All had at least one comorbidity, including immunocompromising conditions (n=15/18; 83%), metabolic conditions (n=8/18; 44%), structural lung disease (n=12/18; 66%) and cardiovascular conditions (n=3/18; 16%). Among persons living with HIV (n=11/18; 61%), 72% (n=8/11) had suppressed HIV viral loads, and 9/11 (81%) had CD4 counts <250 cells/µL. Median (range) length of hospital stay was 4.5 (1 - 15) days. All patients received empirical antibiotics, intravenously in 12/18 (66%); only 5/12 (41%) de-escalated to oral antibiotics. Radiographic findings demonstrated post-tuberculosis lung disease (PTLD) in 50% of patients (n=9/18), of whom 11 (61%) had new ground-glass opacifications, with lobar v. diffuse in 55% (n=6/11) v. 45% (n=5/11). Conclusion: The high prevalence of underlying conditions in adults with RSV-associated SRI, specifically HIV and PTLD, suggests that targeted vaccination in these groups may prevent hospitalisation with RSV-associated SRI. Study synopsis:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.